Work

273P Talazoparib (TALA) for patients with germline BRCA1/2 mutated (gBRCA1/2mut) advanced breast cancer (ABC): Characteristics of patients who experienced hematologic toxicity in the phase III EMBRACA trial

Year: 2021

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2021.08.556

Authors: S.A. Hurvitz, H.S. Rugo, J. Ettl, M. Martin, H. Roche, K-H. Lee, A. Goodwin, T. Usari, S. Lanzalone, C.A. Guenzel, J. Blum, J.K. Litton

Institutions: University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, TUM Klinikum, Technical University of Munich, Universidad Complutense de Madrid, Centro de Investigación Biomédica en Red de Cáncer, Instituto de Investigación Sanitaria Gregorio Marañón, Institut Claudius Regaud, Seoul National University, Seoul National University Hospital, Concord Repatriation General Hospital, Pfizer (Italy), Pfizer (Germany), The University of Texas MD Anderson Cancer Center

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3204724932

FWCI:

Cites:

Cited by:

Related to: 10